What Cost the Supercollider?

For decades, increasingly expensive particle-accelerator projects have been advocated in language almost identical to that now being used to promote the $6 billion superconducting supercoflider (SSC), including promises of "scientific leadership," "spin-offs," of technological and medical "breakthroughs," and so forth. But there is only meager evidence that past promises have been fulfilled and that present promises are any more credible. In a story on the SSC, The New York Times on January 19 s

| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Of course we need to put our best foot forward in the interests of science and technology, as the advocates of the SSC repeatedly state (see "Criteria for Scientific Choices," by Alvin M. Weinberg, Physics Today, March 1964). But that may be just the reason that we should not build the SSC if it will divert scientific manpower—whose supply is severely limited— from tasks with far more promise of making substantial contributions to our scientific and technological development. Japan spends nothing like the vast sums we have spent on particle research. West Germany, which also spends little, is the only country that has an inexpensive, cost-effective in-hospital accelerator facility for the treatment of cancer with fast neutrons—a goal which has thus far eluded our own accelerator establishment.

To many young physicists today, hunting for quarks with a gigantic accelerator may seem much more glamorous than doing materials research with bench-top ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Lawrence Cranberg

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo